Evaluation of carbapenem family antibiotic consumption patterns for controlling common bacterial infections in hospital
Subject Areas :
mohammad mehdi rashidi
1
(Institute of Energy Studies, Tehran, Iran)
Seyed Reza Abtahi
2
(Department of Pharmacology and Toxicology, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran)
F Nojoomi
3
(Associate Professor of Microbiology, School of Medicine, Infectious Diseases Research Center, AJA University of Medical Sciences, Tehran, Iran)
I Mirzaii Dizgah
4
(Professor of Physiology, School of Medicine, Research Center for Cancer Screening and Epidemiology, AJA University of Medical Sciences, Tehran, Iran)
M Darvishi
5
(Associate Professor of Infectious Disease, School of Aerospace and Subaquatic Medicine, Infectious Diseases Research Center, Beasat Hospital, AJA University of Medical Sciences, Tehran, Iran. )
Keywords: Drug consumption pattern, Carbapenems, Meropenem, Imipenem, Intensive care units.,
Abstract :
Antibiotic resistance is a global concern due to the irrational use of antibiotics. Patients hospitalized in intensive care units are exposed to antibiotic resistance due to their high vulnerability. Therefore, this study was performed to investigate the pattern of carbapenem consumption in the intensive care units of Besat Hospital in a period of six months. This study was conducted by studying the records of patients from March 2018 to September 2018 and extracting hospital statistics from the medical records keeping unit and extracting drug consumption data from the pharmacological statistics unit. Occupied bed-day were obtained from the information classification system of the medical records unit and carbapenem consumption statistics from the pharmacological information system. According to evaluation methods of the medicines, the carbapenem use was expressed as DDD/100 bed-day. In total, 203 patients were admitted to intensive care units. The most common cause of carbapenem use was pneumonia (47.8%). In total, 4928.5 grams of meropenem (equivalent to 25.319 in terms of DDD/100 bed-day) and 79.5 grams of imipenem (equivalent to 0.612 in terms of DDD/100 bed-day) were used. From a total of 709 microbial cultures, sensitivity to carbapenems was investigated in only 145 cases (20.45%). 26 cases (17.93%) had sensitivity and 119 cases (82.07%) had resistance to at least one carbapenem (meropenem and imipenem). Acinetobacter baumannii was highly prevalent. Moreover, the consumption of meropenem and imipenem was high. Therefore, there is a need to adhere to the antibiotic monitoring policy for the appropriate use of antibiotics.
1. Adeli O, Moghaddam NM, Farahani RH, Jame SZB. Antibiotics use patterns in intensive care units of five hospitals in Tehran during 2011-2012. Journal of Archives in Military Medicine. 2015;3(3).
2. Balkhy HH, El-Saed A, El-Metwally A, Arabi YM, Aljohany SM, Al Zaibag M, et al. Antimicrobial consumption in five adult intensive care units: a 33-month surveillance study. Antimicrobial Resistance & Infection Control. 2018;7(1):1-9.
3. Zhang D, Cui K, Lu W, Bai H, Zhai Y, Hu S, et al. Evaluation of carbapenem use in a tertiary hospital: antimicrobial stewardship urgently needed. Antimicrobial Resistance & Infection Control. 2019;8(1):1-7.
4. Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. The Lancet. 2005;365(9459):579-87.
5. Ventola CL. The antibiotic resistance crisis: part 1: causes and threats. Pharmacy and therapeutics. 2015;40(4):277.
6. Darvishi M, Forootan M, Nazer MR, Karimi E, Noori M. Nosocomial Infections, Challenges and Threats: A Review Article. Iranian journal of medical microbiology. 2020;14(2):162-81.
7. Raveh D, Levy Y, Schlesinger Y, Greenberg A, Rudensky B, Yinnon A. Longitudinal surveillance of antibiotic use in the hospital. Qjm. 2001;94(3):141-52.
8. Fleming-Dutra KE, Hersh AL, Shapiro DJ, Bartoces M, Enns EA, File TM, et al. Prevalence of inappropriate antibiotic prescriptions among US ambulatory care visits, 2010-2011. Jama. 2016;315(17):1864-73.
9. Fateh Dizji P, Khosravy M, Saeedi AA, Asli M, Sepahvand S, Darvishi M. Prevalence of Clindamycin-resistant Staphylococcus aureus Induced by Macrolide Resistance, Iran, 2019-2021. Iranian Journal of Medical Microbiology. 2023;17(2):256-61.
10. Heidari L, Sepahvand S, Darvishi M, Jafari R. Molecular analysis of PmrA and PmrB genes in colistin-resistant Pseudomonas aeruginosa strains via PCR method. Pakistan Journal of Pharmaceutical
Sciences. 2019;32(3 (Supplementary)):1175-7.
11. Tiotour M, Shaddel M, Aminianfar M, Mirahmadi H, Barzegar G, Solgi R, et al. Identification of Knockdown Resistance Mutations in the Cimex hemipterus (Hemiptera: Cimicidae) in Iran. The American Journal of Tropical Medicine and Hygiene. 2022;107(1):204.
12. Salam MA, Al-Amin MY, Salam MT, Pawar JS, Akhter N, Rabaan AA, et al., editors. Antimicrobial resistance: A growing serious threat for global public health. Healthcare; 2023: MDPI.
13. Sepahvand S, Darvishi M, Mokhtari M, Ali Davarpanah M. Evaluation of genetic diversity of colistin-resistant Acinetobacter baumannii by BOX-PCR and ERIC-PCR: the first report. Future Microbiology. 2022;17(12):917-30.
14. Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. The Lancet. 2022;399(10325):629-55.
15. Axente C, Licker M, Moldovan R, Hogea E, Muntean D, Horhat F, et al. Antimicrobial consumption, costs and resistance patterns: a two year prospective study in a Romanian intensive care unit. BMC infectious diseases. 2017;17(1):1-9.
16. Akhloufi H, Streefkerk R, Melles D, de Steenwinkel J, Schurink C, Verkooijen R, et al. Point prevalence of appropriate antimicrobial therapy in a Dutch university hospital. European journal of clinical microbiology & infectious diseases. 2015;34:1631-7.
17. Pachori P, Gothalwal R, Gandhi P. Emergence of antibiotic resistance Pseudomonas aeruginosa in intensive care unit; a critical review. Genes & diseases. 2019;6(2):109-19.
18. Manjhi M, Das S, Pal M, Saha I, Reddy S. Incidence, risk factors, clinico-microbiological profile, change in ventilator settings needed and outcome of 135 ventilator associated pneumonia cases in pediatric intensive care unit (PICU) of a tertiary care centre in Eastern India. Journal of Pediatric and Neonatal Individualized Medicine (JPNIM). 2018;7(1):e070122-e.
19. Kumar A, Chaudhry D, Goel N, Tanwar S. Epidemiology of Intensive Care Unit-acquired Infections in a Tertiary Care Hospital of North India. Indian Journal of Critical Care Medicine: Peer-reviewed, Official Publication of Indian Society of Critical Care Medicine. 2021;25(12):1427.
20. Labaste F, Grossac J, Bounes FV, Conil J-M, Ruiz S, Seguin T, et al. Risk factors for acquisition of carbapenem-resistance during treatment with carbapenem in the intensive care unit: a prospective study. European Journal of Clinical Microbiology & Infectious Diseases. 2019;38:2077-85.
21. Yang P, Chen Y, Jiang S, Shen P, Lu X, Xiao Y. Association between antibiotic consumption and the rate of carbapenem-resistant Gram-negative bacteria from China based on 153 tertiary hospitals data in 2014. Antimicrobial Resistance & Infection Control. 2018;7(1):1-7.
22. Popović R, Tomić Z, Tomas A, Anđelić N, Vicković S, Jovanović G, et al. Five-year surveillance and correlation of antibiotic consumption and resistance of Gram-negative bacteria at an intensive care unit in Serbia. Journal of Chemotherapy. 2020;32(6):294-303.
23. Kasper D, Fauci A, Hauser S, Longo D, Jameson J, Loscalzo J. Harrison's principles of internal medicine, 19e: Mcgraw-hill New York, NY, USA:; 2015.
24. So JSP, Capule FR, Peña IG, Nacabuan SMJ, Ngo FLU, Robles YR, et al. Drug Utilization Review of Monitored Parenteral Antimicrobials in a Tertiary Care Private Hospital in Cebu City. Acta Medica Philippina. 2020.
25. Grau S, Fondevilla E, Echeverría-Esnal D, Alcorta A, Limon E, Gudiol F. Widespread increase of empirical carbapenem use in acute care hospitals in Catalonia, Spain. Enfermedades infecciosas y microbiologia clinica. 2019;37(1):36-40.
26. Hattab S, Abu-Taha A, Mohalwes M, Duraidy M, Sbaih M. Patterns of antimicrobial consumption and bacterial resistance in intensive care units: a pilot study from Palestine. Palestinian Medical and Pharmaceutical Journal. 2021;7(2):8.
27. Sharma PR, Barman P. Antimicrobial consumption and impact of “Reserve antibiotic indent form” in an intensive care unit. Indian journal of pharmacology. 2010;42(5):297.
28. Erbay A, Bodur H, Akıncı E, Colpan A. Evaluation of antibiotic use in intensive care units of a tertiary care hospital in Turkey. Journal of Hospital infection. 2005;59(1):53-61.
29. Ghaffary S, Entezari Maleki T, Abdollahpor J, Hamishehkar H. Measurement and comparison of inpatient antibiotic use in five different hospitals in Tabriz. Pharmaceutical Sciences. 2017;23(1):37-41.